Curis Funds Internal Development With Further Erivedge Milestones
This article was originally published in The Pink Sheet Daily
Executive Summary
The cancer biotech is making strides with its internal pipeline as it continues to earn royalties and collect milestones on its partnered programs.
You may also be interested in...
Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz
Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.
Curis Set For Transformative Year With Erivedge Skin Cancer Approval
Approved nearly six weeks before the March 8 PDUFA date, Erivedge (vismodegib) will be available to treat advanced basal cell cancers in a week or two for about $7,500 a month wholesale, partner Genentech said.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.